Hemant Surgical Industries Ltd

Hemant Surgical Industries Ltd

₹ 404 -2.23%
29 May - close price
About

Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies[1]

Key Points

Business Overview:[1][2]
HSIL is ISO 9001:2015, ISO 13485:2016 certified and CDSCO compliant company which deals in importing, manufacturing, and marketing medical disposable, surgical equipments and pharmaceutical products including
a) Supply of dialysis equipment, renal care, oxygen concentrators, air mattresses, ultrasound machines and digital thermometers, etc.
b) Design and manufacture of a range of nebulisers, which are
marketed under the company’s AERO brand
c) HSIL also refurbishes second-hand dialysis machines, manufactures
and supplies related accessories, dialysers and haemodialysis solutions

  • Market Cap 526 Cr.
  • Current Price 404
  • High / Low 446 / 90.0
  • Stock P/E 28.9
  • Book Value 106
  • Dividend Yield 0.00 %
  • ROCE 19.6 %
  • ROE 18.1 %
  • Face Value 10.0

Pros

  • Company's working capital requirements have reduced from 43.0 days to 24.4 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -6.07%
  • Debtor days have increased from 87.9 to 106 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Sep 2025 Mar 2026
58 65 167
52 57 152
Operating Profit 5 8 16
OPM % 9% 12% 9%
3 2 4
Interest 1 2 2
Depreciation 1 1 1
Profit before tax 6 7 16
Tax % 19% 25% 22%
5 5 13
EPS in Rs 4.66 4.19 9.76
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
107 232
98 209
Operating Profit 9 23
OPM % 9% 10%
5 6
Interest 2 4
Depreciation 1 2
Profit before tax 10 24
Tax % 23% 23%
8 18
EPS in Rs 7.70 13.95
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 117%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 130%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 321%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Equity Capital 10 13
Reserves 53 125
31 50
54 87
Total Liabilities 148 274
40 53
CWIP 12 0
Investments 1 0
95 221
Total Assets 148 274

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
9 -32
-30 -3
18 69
Net Cash Flow -4 34
Free Cash Flow -26 -34
CFO/OP 118% -119%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025 Mar 2026
Debtor Days 70 106
Inventory Days 208 121
Days Payable 188 146
Cash Conversion Cycle 90 81
Working Capital Days 62 24
ROCE % 20%

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2023 Mar 2024 Mar 2025
Number of Registered Medical Products
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Gross Cash Cycle (GCA Days)
Days ・Standalone data
Manufacturing Infrastructure Footprint
Sq. Ft. ・Standalone data
Number of Distributors in India
Count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026May 2026
73.56% 73.56% 73.56% 73.56% 58.90% 58.90% 52.83%
0.03% 0.00% 0.00% 0.39% 0.15% 0.15% 0.14%
4.26% 1.97% 1.13% 1.11% 10.81% 10.73% 19.94%
22.14% 24.47% 25.31% 24.93% 30.13% 30.21% 27.10%
No. of Shareholders 7221,2291,2481,229758841948

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents